699 related articles for article (PubMed ID: 11964481)
1. Role of prostacyclin in the cardiovascular response to thromboxane A2.
Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA
Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481
[TBL] [Abstract][Full Text] [Related]
2. Biomedicine. Back to an aspirin a day?
Vane JR
Science; 2002 Apr; 296(5567):474-5. PubMed ID: 11964462
[No Abstract] [Full Text] [Related]
3. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
[TBL] [Abstract][Full Text] [Related]
4. COX-2-derived prostacyclin confers atheroprotection on female mice.
Egan KM; Lawson JA; Fries S; Koller B; Rader DJ; Smyth EM; Fitzgerald GA
Science; 2004 Dec; 306(5703):1954-7. PubMed ID: 15550624
[TBL] [Abstract][Full Text] [Related]
5. COX-2-derived prostacyclin modulates vascular remodeling.
Rudic RD; Brinster D; Cheng Y; Fries S; Song WL; Austin S; Coffman TM; FitzGerald GA
Circ Res; 2005 Jun; 96(12):1240-7. PubMed ID: 15905461
[TBL] [Abstract][Full Text] [Related]
6. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
7. Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation.
Haider A; Lee I; Grabarek J; Darzynkiewicz Z; Ferreri NR
Circulation; 2003 Aug; 108(8):1015-21. PubMed ID: 12912810
[TBL] [Abstract][Full Text] [Related]
8. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
9. [Terutroban and endothelial TP receptors in atherogenesis].
Verbeuren TJ
Med Sci (Paris); 2006 Apr; 22(4):437-43. PubMed ID: 16597416
[TBL] [Abstract][Full Text] [Related]
10. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
Kobayashi T; Tahara Y; Matsumoto M; Iguchi M; Sano H; Murayama T; Arai H; Oida H; Yurugi-Kobayashi T; Yamashita JK; Katagiri H; Majima M; Yokode M; Kita T; Narumiya S
J Clin Invest; 2004 Sep; 114(6):784-94. PubMed ID: 15372102
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of lipoxin A4 receptor by thromboxane A2 signaling in RAW246.7 cells in vitro and bleomycin-induced lung fibrosis in vivo.
Sato Y; Kitasato H; Murakami Y; Hashimoto A; Endo H; Kondo H; Inoue M; Hayashi I
Biomed Pharmacother; 2004; 58(6-7):381-7. PubMed ID: 15271420
[TBL] [Abstract][Full Text] [Related]
12. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective prostacyclin signaling in vascular smooth muscle.
Fetalvero KM; Martin KA; Hwa J
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):109-18. PubMed ID: 17164138
[TBL] [Abstract][Full Text] [Related]
14. Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries.
Liu B; Luo W; Zhang Y; Li H; Zhu N; Huang D; Zhou Y
Exp Physiol; 2012 Feb; 97(2):277-89. PubMed ID: 22080487
[TBL] [Abstract][Full Text] [Related]
15. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
Cayatte AJ; Du Y; Oliver-Krasinski J; Lavielle G; Verbeuren TJ; Cohen RA
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1724-8. PubMed ID: 10894809
[TBL] [Abstract][Full Text] [Related]
16. Cyclo-oxygenase products and atherothrombosis.
FitzGerald GA; Austin S; Egan K; Cheng Y; Pratico D
Ann Med; 2000 Dec; 32 Suppl 1():21-6. PubMed ID: 11209977
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
Belton OA; Duffy A; Toomey S; Fitzgerald DJ
Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
19. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.
Thomas DW; Mannon RB; Mannon PJ; Latour A; Oliver JA; Hoffman M; Smithies O; Koller BH; Coffman TM
J Clin Invest; 1998 Dec; 102(11):1994-2001. PubMed ID: 9835625
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1beta-stimulated rat aortic smooth muscle cells.
Shiokoshi T; Ohsaki Y; Kawabe J; Fujino T; Kikuchi K
J Hypertens; 2002 Mar; 20(3):455-61. PubMed ID: 11875313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
